DLL3 CAR-T Therapy Targeting Brain Tumors

Shenzhen Geno-Immune Medical Institute

Status and phase

Enrolling

Phase 2

Phase 1

Conditions

Glioblastoma of Cerebellum

Treatments

Biological: 4SCAR DLL3 T cells

Study type

Interventional

Funder types

Other

Identifiers

NCT07180927

GIMI-IRB-25003

Details and patient eligibility

About

The purpose of this study is to assess the feasibility, safety and efficacy of Delta-like ligand 3 (DLL3)-specific CAR-T cell therapy in patients with DLL3 positive brain tumors including glioblastomas and diffused intrinsic pontine or midline gliomas (DIPG or DMG). Another goal of the study is to learn more about the function of the anti-DLL3 CAR-T cells and their persistency in patients.

Full description

Glioblastoma (GBM) and other aggressive brain tumors remain among the most challenging cancers to treat, with limited therapeutic options and poor survival rates. GBM is known to express increased levels of certain antigens that can be targeted by T cells including chimeric antigen receptor-modified T (CAR-T) cells.

One promising target in this effort is DLL3, a protein highly expressed on the surface of certain tumor cells including GBM/DIPG/DMG and other central nervous system malignancies but with minimal presence in normal tissues. This expression pattern makes DLL3 an attractive target for precision CAR-T therapy treating brain tumors, which involves engineering a patient's own T cells to recognize and eliminate cancer cells expressing this specific marker.

This study aims to evaluate the safety, feasibility, and preliminary efficacy of DLL3-directed CAR-T cells in patients with recurrent or refractory brain tumors. These studies represent a critical step toward harnessing the immune system to fight traditionally treatment-resistant cancers, offering new hope for patients with few other options.

Enrollment

30 estimated patients

Sex

All

Ages

2 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

abilities to understand and the willingness to provide written informed consent;
patients are ≥ 2 and ≤ 70 years old;
recurrent or refractory brain tumor patients with measurable lesions. Patients have received standard care of medication, such as gross total resection with concurrent radio-chemotherapy (~54 - 60 Gy, TMZ). Patients must either not be receiving dexamethasone or receiving ≤ 4 mg/day at the time of leukopheresis;
Karnofsky performance score (KPS) ≥ 60;
life expectancy >3 months;
satisfactory bone marrow, liver and kidney functions as defined by the following: absolute neutrophile count ≥ 1500/mm^3; hemoglobin > 10 g/dL; platelets > 100000 /mm^3; Bilirubin < 1.5×ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5×ULN; creatinine < 1.5×ULN;
peripheral blood absolute lymphocyte count must be above 0.8×10^9/L;
satisfactory heart functions;
patients must be willing to follow the instructions of doctors;
women of reproductive potential (between 15 and 49 years old) must have a negative pregnancy test within 7 days of study start. Male and female patients of reproductive potential must agree to use birth control during the study and 3 months post study.

Exclusion criteria

a prior history of gliadel implantation 4 weeks before this study start or currently receiving antibody based therapies;
HIV positive;
tuberculosis infection not under control;
history of autoimmune disease, or other diseases require long-term administration of steroids or immunosuppressive therapies;
history of allergic disease, or allergy to immune cells or study product excipients;
patients already actively enrolled in other immune cell clinical study; patients, in the opinion of investigators, may not be eligible or not able to comply with the study.